Collegium Pharmaceutical Inc (NASDAQ:COLL) insider Alison B. Fleming sold 6,928 shares of the stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $19.07, for a total transaction of $132,116.96. Following the completion of the sale, the insider now directly owns 32,651 shares of the company’s stock, valued at $622,654.57. The transaction was disclosed in a filing with the SEC, which is available at this link.

Collegium Pharmaceutical Inc (NASDAQ COLL) opened at $20.02 on Monday. Collegium Pharmaceutical Inc has a 52 week low of $7.37 and a 52 week high of $21.38. The firm has a market capitalization of $651.90, a P/E ratio of -6.72 and a beta of 0.42.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative return on equity of 77.11% and a negative net margin of 447.83%. The business had revenue of $11.95 million during the quarter, compared to the consensus estimate of $5.31 million. During the same period in the prior year, the company posted ($1.13) EPS. The firm’s revenue for the quarter was up 2814.6% compared to the same quarter last year. equities analysts forecast that Collegium Pharmaceutical Inc will post -2.52 EPS for the current year.

A number of hedge funds have recently bought and sold shares of the business. Nationwide Fund Advisors boosted its stake in Collegium Pharmaceutical by 27.8% in the 2nd quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock worth $161,000 after purchasing an additional 2,802 shares during the period. Royal Bank of Canada boosted its stake in Collegium Pharmaceutical by 12.7% in the 2nd quarter. Royal Bank of Canada now owns 29,139 shares of the specialty pharmaceutical company’s stock worth $365,000 after purchasing an additional 3,285 shares during the period. Wells Fargo & Company MN boosted its stake in Collegium Pharmaceutical by 12.8% in the 3rd quarter. Wells Fargo & Company MN now owns 45,254 shares of the specialty pharmaceutical company’s stock worth $475,000 after purchasing an additional 5,136 shares during the period. The Manufacturers Life Insurance Company boosted its stake in Collegium Pharmaceutical by 38.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,621 shares of the specialty pharmaceutical company’s stock worth $233,000 after purchasing an additional 5,167 shares during the period. Finally, California State Teachers Retirement System boosted its stake in Collegium Pharmaceutical by 21.5% in the 2nd quarter. California State Teachers Retirement System now owns 40,195 shares of the specialty pharmaceutical company’s stock worth $503,000 after purchasing an additional 7,100 shares during the period. Institutional investors and hedge funds own 79.98% of the company’s stock.

Several research firms recently issued reports on COLL. BidaskClub raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Friday, December 29th. Piper Jaffray Companies set a $23.00 target price on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Thursday, December 14th. Needham & Company LLC increased their target price on shares of Collegium Pharmaceutical from $25.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, December 5th. They noted that the move was a valuation call. Jefferies Group increased their target price on shares of Collegium Pharmaceutical to $27.00 and gave the stock a “buy” rating in a report on Tuesday, December 5th. Finally, HC Wainwright reissued a “buy” rating and issued a $21.00 target price on shares of Collegium Pharmaceutical in a report on Friday, November 17th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $23.33.

TRADEMARK VIOLATION WARNING: “Collegium Pharmaceutical Inc (COLL) Insider Sells $132,116.96 in Stock” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.thecerbatgem.com/2018/01/15/collegium-pharmaceutical-inc-coll-insider-sells-132116-96-in-stock.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Receive News & Stock Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related stocks with our FREE daily email newsletter.